Semaglutide and Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Fibrosis: An Exploratory Indirect Comparison.

This is an indirect, cross-trial comparison of semaglutide and resmetirom for MASH with fibrosis, not a head-to-head trial. Indirect comparisons carry substantial methodological caveats and cannot establish superiority. Semaglutide is a genuine subject, so it carries moderate signal, but conclusions should be read cautiously given no abstract detail and the exploratory design.